Re: Apabetalone’s Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell
posted on
Mar 18, 2021 10:33AM
I still strongly feel that the elephant on the table is that RVX still doesn't know what the full set of applications are and therefore what the full market value of ABL actually is yet given its many potential possibilities.
And because of this, RVX is not going to sell it for a buck when they can make 10. And BP isn't going to pay 10 bucks when it may be only worth one.
So if I'm RVX and BP (both) I'd buy as much time as possible to truly understand what it is that they have before striking a deal or vs going chapter 11 (or whatever bankruptcy is called in Canada)
Clearly the announcements are picking up speed in very reputable peer review journals and we have multiple plays now for ABL.
I have no idea but it feels like something has to give this year.
10BagR